

Associations between enlarged perivascular spaces and clinical manifestations: a meta-analysis

Rui Zhai, Yingxiao Ji, Jihong Liu, Min Chen, Zhipeng Cai, Litao Li*

Department of Neurology, Hebei General Hospital, Shijiazhuang, Hebei Province, China

Submitted: 12 May 2022; **Accepted:** 24 August 2022

Online publication: 9 September 2022

Arch Med Sci

DOI: <https://doi.org/10.5114/aoms/152945>

Copyright © 2022 Termedia & Banach

***Corresponding author:**

Litao Li

Department of Neurology

Hebei General Hospital

Shijiazhuang, Hebei Province,

China

E-mail: dingding51800@163.

com

Abstract

Introduction: Enlarged perivascular spaces (EPVS) are ubiquitous in the elderly and have an insidious onset. Their correlation with clinical symptoms is easily overlooked and controversial. We conducted a meta-analysis to investigate the clinical outcomes associated with EPVS.

Methods: Relevant studies published up to April 2022 were extracted from PubMed, Embase, Cochrane, OVID, and Web of Science. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to estimate the strength of the associations.

Results: Of the 6622 articles identified, 32 studies were eligible, including a total of 19,987 people. EPVS were associated with an increased risk of cognitive impairment (OR = 1.60, 95% CI: 1.39–1.81), motor impairment (OR = 2.24, 95% CI: 1.22–3.25), sleep disturbance (OR = 1.81, 95% CI: 1.34–2.28), and depressive symptoms (OR = 1.54, 95% CI: 1.14–1.95), but was not significantly associated with the occurrence of stroke (OR = 0.97, 95% CI: 0.74–1.21). Results of subgroup analysis showed that basal ganglia (BG) EPVS were more strongly associated with cognitive impairment (OR = 2.19, 95% CI: 1.72–2.65) and sleep disturbance (OR = 1.74, 95% CI: 1.20–2.29).

Conclusions: Our findings suggest that EPVS are associated with cognitive impairment, motor impairment, sleep disturbance, and depressive symptoms. These findings may provide a basis for further investigation of the clinical significance of EPVS.

Key words: enlarged perivascular spaces, clinical symptoms, meta-analysis.

Introduction

The importance of enlarged perivascular spaces (EPVS, also known as Virchow–Robin spaces) as an imaging marker of cerebral small vessel disease (CSVD) has been recognized [1]. With age, the number and volume of EPVS gradually increase [2], and more than 80% of people over the age of 70 have enlarged perivascular spaces [3]. Normal perivascular spaces (PVS) are important for maintaining brain health and are thought to function as part of the brain's perivascular clearance system, serving as a pathway for fluid transport, cerebrospinal fluid–interstitial fluid (CSF–ISF) exchange, and clearance of metabolic wastes from the brain. On MRI, PVS are typically visible as small fluid-filled spaces, whereas enlarged PVS (EPVS) are defined as prominent PVS that meet established radiological criteria. EPVS typically have a diameter of less than 3 mm, although larger spaces may also be observed [4]. EPVS have a smooth and clear boundary on MRI, which is round, oval, or linear, consistent with

the course of perforating arteries, and have the same signal as CSF on T2WI, T1WI, and FLAIR sequences [4]. PVS expansion suggests brain micro-circulation disorders and brain clearance mechanism dysfunction [5]. EPVS are mainly distributed in the basal ganglia (BG), center semiovale (CS), midbrain, and hippocampus (HP) [6]. At present, visual semi-quantitative methods are often used to assess the severity of EPVS, but the methods are not uniform. The most commonly used method now is the Potter assessment method [7]. The basal ganglia and the center of the semiovale of the cerebral hemisphere on the side with heavier EPVS load were assessed with a score of 0-4, and the midbrain was assessed with a score of 0-1.

Recent years have witnessed a gradual increase in research on EPVS and clinical symptoms, such as cognitive impairment, movement disorders, depressive symptoms, sleep disorders, and stroke [8–13], which impose huge social and economic burdens [14]. EPVS are closely related to age, and population aging is an increasingly important public health concern [15]. Therefore, understanding the clinical significance of a high EPVS burden on MRI has important clinical implications. However, PVS are characterized by an insidious clinical course associated with cerebral small vessel disease, and their imaging appearance can be easily confused with that of lacunes. Some scholars believe that EPVS represent a pathological manifestation of age-related brain tissue loss and are therefore an incidental finding. In addition, current research on neurological dysfunction, such as dementia and stroke, has largely focused on blood vessels and neurons/glia cells. These factors may contribute to EPVS receiving insufficient attention from clinicians [1, 16]. It should still be noted that the relevance and importance of EPVS to neurological disorders is still controversial [3, 17]. For example, Van Sloten [18] found that EPVS were significantly associated with the appearance of depressive symptoms over time. However, Zhang *et al.* [19] found no significant correlation between EPVS and depressive symptoms in a study of CSVD

and post-stroke depression. Similarly, in studies investigating the association between EPVS and sleep disorders, Shuna Yang *et al.* [20] and Burnett *et al.* [12] obtained conflicting results. Studies investigating the association between EPVS and cognitive impairment, such as those by Arba *et al.* [21] and Sim *et al.* [22], have also obtained inconsistent results. In addition, the mechanisms underlying the development of EPVS in different brain regions and their possible clinical consequences remain controversial [23]. Therefore, we conducted a meta-analysis to investigate the association between EPVS in different brain regions and clinical outcomes.

Methods

Search strategy for the literature

The meta-analysis was reported in accordance with the PRISMA guidelines. We searched PubMed, Embase, Cochrane, OVID, and Web of Science databases from the date of establishment to April 2022 using predefined search terms, and manually screened the reference lists of relevant articles. The study was conducted by three independent investigators, and disagreements were resolved by discussion. The search strategy and keywords are presented in Table I.

Inclusion and exclusion criteria

We aimed to include all papers reporting EPVS related to cognitive impairment, motor impairment, sleep disturbance, depressive symptoms, and stroke. We excluded studies without effect estimates such as odds ratios (ORs), relative risks (RRs), hazard ratios (HRs), and confidence intervals (CI), and excluded case reports, animal studies, and reviews. We also excluded studies where EPVS occur in inflammatory conditions (e.g., multiple sclerosis, lupus) and inherited CSVD (e.g., cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, CADASIL). Additionally, we excluded nervous system diseases (such as traumatic brain injury, brain tumor, hy-

Table I. The search strategy of PubMed

Search	Query
#1	(((((Enlarged Perivascular Space[MeSH Major Topic] OR (Enlarged Virchow-Robin Spaces[Title/Abstract])) OR (Perivascular Spaces Enlargement[Title/Abstract])) OR (Virchow-Robin Spaces Enlargement[Title/Abstract])) OR (perivascular spaces[Title/Abstract])) OR (Virchow-robin spaces[Title/Abstract]))) OR (Enlarged Perivascular Spaces[Title/Abstract])
#2	((Clinical[Title/Abstract]) OR (Clinical Symptoms[Title/Abstract])) OR (Clinical Manifestation[Title/Abstract])
#3	((((Magnetic Resonance Imaging[Title/Abstract]) OR (Imaging[Title/Abstract])) OR (MR Tomography[Title/Abstract])) OR (MRI[Title/Abstract])) OR (fMRI[Title/Abstract])
#4	#2 OR #3
#5	#1 And #4

drocephalus, encephalitis, secondary and inherited Parkinson's syndrome) that may cause relevant clinical symptoms of the participant.

Data extraction

We removed duplicate articles, deleted irrelevant articles based on titles and abstracts, and included eligible articles by reading the full text. The extracted data were as follows: first author name, year of publication, country or region of publication, study type, study samples, main clinical symptoms, follow-up time, EPVS location, association outcomes (ORs or RRs or HRs and corresponding 95% CI).

Quality score assessment

The Newcastle-Ottawa Scale (NOS) was used to evaluate the quality of the study [24]. On this scale, a score of 9 is considered high quality, a score of 7–8 is considered moderate quality, and a score below 7 is considered low quality. Two reviewers independently assessed quality, and differences were resolved through discussion with a third reviewer.

Statistical analysis

We performed meta-analyses using Stata software version 15.1. Multivariate-adjusted ORs and 95% CI were plotted, and summary ORs were generated. Inter-study heterogeneity was assessed using the I^2 test, with a random-effects model when

$I^2 > 50\%$, and a random-effects model when $I^2 < 50\%$ [25]. The z-test was used to assess the significance of the pooled ORs, and $p < 0.05$ was considered statistically significant. Sensitivity analyses were performed to evaluate the robustness of the results. Potential publication bias was investigated using Begg's test. Subgroup analyses were performed to explore sources of heterogeneity.

Results

The initial search in PubMed, Embase, Cochrane, OVID, and Web of Science identified 6622 articles. In total, 32 articles ($n = 19,987$) met our inclusion criteria (Figure 1).

Characteristics of 32 studies included in the meta-analysis

This systematic review and meta-analysis summarized data from 32 studies ($n = 19,987$), including 14 cross-sectional studies, 11 prospective studies, and 7 retrospective studies. They come from different countries and regions, including China, France, the United Kingdom, the United States, South Korea, Sweden, the Netherlands, etc. In our article, we mainly divide the regions of EPVS into BG, CS, and HP. According to anatomical characteristics, Swiss cheese striatum enlarged perivascular spaces (SCS EPVS) were classified into BG EPVS, and white matter enlarged perivascular spaces (WM EPVS) were classified into CS EPVS.

For cognitive impairment, 12 studies ($n = 9205$) met our inclusion criteria [12, 21, 22, 26–34]. For




Figure 1. Summary of evidence search and selection

movement disorders, 5 studies ($n = 1010$) met our inclusion criteria [9, 12, 35–37]. For sleep disturbances, 8 studies ($n = 1846$) met our inclusion criteria [11, 12, 20, 38–42]. For depressive symptoms, 5 studies ($n = 3465$) met our inclusion criteria [10, 12, 18, 19, 39]. For stroke, 7 studies ($n = 6867$) met our inclusion criteria [13, 31, 43–47]. The EPVS scoring scale used is mainly the Potter scale, and some studies have used other scales. The included studies mainly used 1.5 T or 3.0 T MRI scanners. Studies with a quality-assessment score of ≥ 7 were included. Basic characteristics and quality assessments of the included studies are shown in Tables II–IV.

Correlation between EPVS and clinical symptoms

Cognitive impairment

Twelve studies ($n = 9205$) reported on associations between cognitive impairment and EPVS in the BG, CS, or hippocampus. EPVS was significantly associated with cognitive impairment (OR = 1.60, 95% CI: 1.39–1.81, $I^2 = 22.8\%$, $p = 0.184$), with the strongest association observed for BG (OR = 2.19, 95% CI: 1.72–2.65, $I^2 = 0.0\%$, $p = 0.550$), followed by CS (OR = 1.52, 95% CI: 1.26–1.77, $I^2 = 0.0\%$, $p = 0.584$). However, hippocampal EPVS were not significantly associated with cognitive impairment (OR = 1.02, 95% CI: 0.39–1.65, $I^2 = 0.0\%$, $p = 0.393$) (Table II, Figure 2).

Motor impairment

We found a significant association in 946 participants from five studies of EPVS with motor impairment (OR = 2.24, 95% CI: 1.22–3.25, $I^2 = 0.0\%$, $p = 0.734$) (Table II, Figure 3).

Sleep disturbance

In 1846 participants from eight studies, EPVS was significantly associated with sleep disturbance (OR = 1.81, 95% CI: 1.34–2.28, $I^2 = 0.0\%$, $p = 0.982$), especially in BG EPVS (OR = 1.74, 95% CI: 1.20–2.29, $I^2 = 0.0\%$, $p = 0.927$). There were insufficient data to compare CS EPVS and sleep disturbance (Table II, Figure 3).

Depressive symptoms

Five studies ($n = 3465$) found that depressive symptoms were associated with EPVS (OR = 1.54, 95% CI: 1.14–1.95, $I^2 = 0.0\%$, $p = 0.704$) (Table II, Figure 4).

Stroke

Seven studies ($n = 6867$) found no association between stroke and EPVS (OR = 0.97, 95% CI:

0.74–1.21, $I^2 = 63.8\%$, $p = 0.001$) (Table II, Figure 4). We also found no significant associations in further subgroup analyses according to the brain region in which EPVS were located.

Sensitivity analyses and publication bias

The purpose of the sensitivity analyses was to detect whether any of the included studies would affect the primary outcome of the meta-analysis. The OR values did not change significantly when either study was excluded (Supplementary Figures S1–S5 show the results of the sensitivity analyses). Begg's test based on the OR value and SE showed no publication bias (Table V).

Discussion

We investigated the correlation between EPVS and clinical symptoms using meta-analysis. Since BG EPVS and CS EPVS have different formation mechanisms, we performed a subgroup analysis to explore whether there are differences in their impact on clinical symptoms. Our findings showed that EPVS were associated with cognitive impairment, motor impairment, sleep disturbance, and depressive symptoms, but not with stroke.

In recent years, many studies have shown that EPVS are associated with the occurrence of cognitive impairment [8]. Impaired cortical cholinergic pathways can lead to cognitive impairment, and a high burden of EPVS may impair the cortical cholinergic pathways, thereby contributing to cognitive decline [48]. However, these findings remain controversial. For example, a prospective study by Yilmaz *et al.* [31] showed that EPVS were not associated with the risk of dementia. This finding may have been influenced by the small number of participants with EPVS included in the study. Our findings also show that BG EPVS were more strongly associated with cognitive impairment than CS EPVS, which may be related to their different anatomical characteristics and formation mechanisms. Studies have shown that BG EPVS are more strongly associated with age and hypertension [17], and CS EPVS are more strongly related to cerebral amyloid angiopathy (CAA) [30]. In light of our findings, we speculate that vascular risk factors such as age and hypertension may have a greater influence on cognitive impairment than CAA; however, further clinical studies are needed to investigate this hypothesis.

Several recent human studies have reported an association between sleep and EPVS. The perivascular space is a critical pathway for lymphatic flow and an important fluid waste removal system that may be associated with compensatory changes in human sleep physiology [49, 50]. Larger PVS volumes have been reported to be associated with periodic limb movements during sleep [51] and

Table II. Characteristics of studies included in the meta-analysis

Study	Year	Total	Study type	Fol- low-up time	Clinical symptoms	OR (95% CI)	Brain region	Geographic region
Cognitive impairment								
Zhu <i>et al.</i> [26]	2010	1778	Prospective	4 years	Dementia	5.8 (1.2–28.4) 9.8 (1.7–55.3)	BG WM	France
Burnett <i>et al.</i> [12]	2014	79	Retrospec- tive	/	Dementia	1.57 (0.48–5.13)	SCS	Minnesota
Yao <i>et al.</i> [27]	2014	1818	Prospective	6.12 years	Dementia	0.95 (0.50–1.80)	HP	Dijon
Arba <i>et al.</i> [28]	2016	234	Retrospec- tive	/	PSCI	2.66 (1.82–3.87) 2.08 (1.42–3.05)	BG CS	VISTA
Arba <i>et al.</i> [21]	2016	430	Retrospec- tive	/	Cognitive disorder	2.52 (1.90–3.35) 1.67 (1.25–2.18)	BG CS	VISTA
Riba-Llena <i>et al.</i> [29]	2016	733	Prospective	8 years	MCI	1.88 (1.03–3.41)	BG	Barcelona
Shams <i>et al.</i> [30]	2017	1504	Cross-sec- tional	/	Vascular dementia	11.1 (1.1–112.2) 1.3 (0.6–2.9)	BG CS	Sweden
Yilmaz <i>et al.</i> [31]	2018	1651	Prospective	7.2 years	Dementia	0.97 (0.35–2.72)	BG	Netherlands
Xiong <i>et al.</i> [32]	2018	158	Cross-sec- tional	/	Dementia	1.283 (0.967–1.703)	CS	Massachu- setts
Banerjee <i>et al.</i> [33]	2019	117	Prospective	1 year	Cognitive impairment	2.60 (0.74–9.19) 1.83 (1.06–3.15)	BG CS	UK
Sim <i>et al.</i> [22]	2020	109	Cross-sec- tional	/	Memo- ry function	2.142 (–0.515– 4.799)	HP	South Korea
Paradise <i>et al.</i> [34]	2021	414	Prospective	6 years	Dementia	3.25(1.14–9.30) 1.77(0.58–5.39)	BG CS	Sydney
Motor disorder								
Wan <i>et al.</i> [36]	2018	137	Cross-sec- tional	/	PIGD	2.97 (0.98–9.03)	CS	China
Lioutas <i>et al.</i> [35]	2018	175	Retrospec- tive	/	Functional independ- ence	1.4 (0.34–5.77)	BG	USA
Del Brutto <i>et al.</i> [37]	2019	288	Cross-sec- tional	/	risk of falls	3.36 (1.85–6.09)	BG	Atahualpa
Heiland <i>et al.</i> [9]	2021	331	Prospective	9 years	Walking speed lim- itation	2.13 (1.04–4.36)	/	Sweden
Burnett <i>et al.</i> [12]	2014	79	Retrospec- tive	/	Any movement disorder	1.47 (0.43–5.04)	SCS	Minnesota
Sleep disturbance								
Song <i>et al.</i> [38]	2017	170	Cross-sec- tional	/	Moder- ate-to-se- vere (AHI ≥ 15)	3.64 (1.02–13.01)	/	South Korea
Wang <i>et al.</i> [42]	2020	106	Cross-sec- tional	/	Arl	2.108 (1.032–4.017)	/	China
Ramirez <i>et al.</i> [11]	2021	153	Cross-sec- tional	/	Daytime Dysfunction	5.31 (1.38–22.26)	BG	ONDRI
Del Brutto <i>et al.</i> [39]	2019	338	Cross-sec- tional	/	Sleep quality	1.68 (1.01–2.79)	BG	Atahualpa

Table II. Cont.

Study	Year	Total	Study type	Fol- low-up time	Clinical symptoms	OR (95% CI)	Brain region	Geographic region
Del Brutto <i>et al.</i> [40]	2020	146	Cross-sec- tional	/	PLMS	1.36 (0.56–3.33)	BG	Atahualpa
Burnett <i>et al.</i> [12]	2014	79	Retrospec- tive	/	Any sleep disorder	1.37 (0.37–4.97)	SCS	Minnesota
Aribisala <i>et al.</i> [41]	2020	457	Cross-sec- tional	/	Interrupted sleep	1.84 (1.08–3.15)	BG	Scotland
Yang <i>et al.</i> [20]	2022	398	Retrospec- tive	/	Poor sleep quality	2.125 (1.113–4.058) 1.882 (1.005– 3.527)	BG WM	China
Depressive symptoms								
Van Sloten <i>et al.</i> [18]	2015	1949	Prospective	5 years	Depression	3.44 (1.71–6.91)	/	Reykjavik
Liang <i>et al.</i> [10]	2018	725	Cross-sec- tional	/	PSD	1.49 (1.04–2.13)	CS	China
Zhang <i>et al.</i> [19]	2016	374	Cross-sec- tional	/	PSD	1.557 (0.958–2.530)	/	China
Del Brutto <i>et al.</i> [39]	2019	338	Cross-sec- tional	/	Depression	1.359 (0.608–3.039)	BG	Atahualpa
Burnett <i>et al.</i> [12]	2014	79	Retrospec- tive	/	Depression	1.57 (0.48–5.13)	SCS	Minnesota
Stroke								
Yilmaz <i>et al.</i> [31]	2018	1651	Prospective	7.2 years	Stroke	1.80 (0.71–4.59)	BG	Netherlands
Charidimou <i>et al.</i> [13]	2013	121	Retrospec- tive	/	ICH	3.58 (1.70–7.54) 0.74 (0.35–1.57)	BG CS	UK and Bel- gium
Xu <i>et al.</i> [46]	2021	167	Cross-sec- tional	/	Large hematoma volume	0.395 (0.147–1.064)	/	China
Zhang <i>et al.</i> [45]	2020	1204	Prospective	3 years	Stroke	3.34 (0.78–14.37)	/	China
Gutierrez <i>et al.</i> [43]	2017	1228	Prospective	9 ±2 years	Stroke	0.9 (0.60–1.61)	/	Manhattan
Lau <i>et al.</i> [44]	2017	2002	Prospective	42 ±23 months	Ischemic stroke	1.82 (1.18–2.80)	BG	UK and China
					Intracere- bral hemor- rhage	2.58 (0.97–6.89)	BG	
					Recurrent stroke	1.94 (1.31–2.89)	BG	
					Ischemic stroke	0.83 (0.54–1.28)	CS	
					Intracere- bral hemor- rhage	1.36 (0.51–3.59)	CS	
					Recurrent stroke	0.89 (0.60– 1.33)	CS	
Song <i>et al.</i> [47]	2021	494	Retrospec- tive	/	HT	0.638 (0.454–0.897) 0.690 (0.502–0.949)	BG CS	China

PSCI – post-stroke cognitive impairment, VISTA – Virtual International Stroke Trial Archive, MCI – mild cognitive impairment, PIGD – postural instability and gait disability, AHI – apnea-hypopnea index, Ari – arousal index, PSD – poststroke depression, HT – hemorrhagic transformation, HR – hazard ratio, OR – odds ratio, BG – basal ganglia, CS – centrum semiovale, WM – white matter, SCS – Swiss cheese striatum, HP – hippocampus, ICH – intracerebral hemorrhage, PLMS – periodic limb movements during sleep, ONDRI – Ontario Neurodegenerative Disease Research Initiative.

Table III. Eight questions of included study quality were evaluated according to Newcastle-Ottawa Scale (NOS) evaluation criteria

Prospective		
1. Are EPVS major exposure factors?	YES (1)	NO (0)
2. Are the non-exposed group and the exposed group from the same population?	YES (1)	NO (0)
3. Did the MRI protocol for EPVS assessment include T1-, T2-, and FLAIR-weighted sequences?	YES (1)	NO (0)
4. Were the investigators ignorant of the patient's clinical symptoms when determining EPVS?	YES (1)	NO (0)
5. Did the study control for the most important confounders (sex, age)	YES (2)	NO (0)
6. Is the assessment of clinical symptoms adequate?	YES (1)	NO (0)
7. Is the follow-up period long enough?	YES (1)	NO (0)
8. Is the follow-up adequate?	Complete follow-up or a small number of studies lost to follow-up without introducing bias (1)	Lost to follow-up but not described or follow-up not described (0)
Retrospective or cross-sectional		
1. Were clinical symptoms assessed by professionally trained personnel?	YES (1)	NO (0)
2. Were the cases representative of the target population?	YES (1)	NO (0)
3. Were the controls drawn from the same population as the cases?	YES (1)	NO (0)
4. Were the controls free of the target clinical symptoms?	YES (1)	NO (0)
5. Did the study control for the most important confounders (sex, age)?	YES (2)	NO (0)
6. Did the MRI protocol for EPVS assessment include T1-, T2-, and FLAIR-weighted sequences?	YES (1)	NO (0)
7. Were the same assessment criteria used to evaluate EPVS severity in the case and control groups?	YES (1)	NO (0)
8. Did the case group and the control group have the same non-response rate?	YES (1)	NO (0)

NOS – Newcastle-Ottawa Scale, EPVS – enlarged perivascular spaces, MRI – magnetic resonance imaging.

lower sleep quality [52]. These observations reflect the effect of sleep deprivation on the structure of the perivascular space. However, one study found that the association between sleep disturbance and EPVS disappeared after adjusting for relevant confounders [39]. After subgroup analysis, we found that BG EPVS were more significantly associated with sleep disturbance. There are few studies on CS EPVS and sleep disturbance, which may be related to the anatomical structure of cerebrospinal fluid drainage. BG EPVS can communicate directly with the basal cisterns, while CS EPVS communicate with subarachnoid CSF at certain locations. This may result in a greater role for BG EPVS in CSF drainage than CS EPVS, potentially contributing to the stronger association between BG EPVS and sleep disturbances [53, 54].

Our results show that EPVS were associated with motor impairment. Unfortunately, we did not perform a subgroup analysis due to the small number of eligible studies. A prospective study with a 9-year follow-up showed that the highest tertile of EPVS burden was associated with a 2.13-

fold higher risk of motor impairment (HR = 2.13; 95% CI: 1.04–4.36), suggesting that motor impairment may be associated with the burden and progression of EPVS [9]. However, the study by Pinter *et al.* [55] showed that white matter hyperintensities (WMH) were a significant predictor of gait and balance impairment, whereas EPVS was not significantly associated with movement impairment. This discrepancy may partly reflect differences in study populations, as the study mainly included non-disabled, community-dwelling older adults with lower overall CSVD scores, potentially attenuating the observed association.

Our findings suggest that EPVS are associated with depressive symptoms. Depression in later life is associated with cerebrovascular disease, and treatment resistance may be associated with vascular lesions in the white matter and basal ganglia [56]. Common sites of EPVS overlap with emotion regulation pathways (such as frontal-subcortical loops, cingulate-cortical loops, and cortico-basal ganglia loops), potentially disrupting neural circuits involved in emotion regulation and contribut-

Table IV. Quality assessment of the included studies using eight criteria

Study	Year	1	2	3	4	5	6	7	8	Total
Prospective										
Zhu <i>et al.</i> [26]	2010	Y	N	Y	Y	Y	Y	Y	Y	8
Yao <i>et al.</i> [27]	2014	Y	N	Y	Y	Y	Y	Y	Y	8
Van Sloten <i>et al.</i> [18]	2015	Y	Y	Y	Y	Y	N	Y	Y	8
Riba-Llena <i>et al.</i> [29]	2016	Y	Y	Y	N	Y	N	Y	Y	7
Gutierrez <i>et al.</i> [43]	2017	Y	N	Y	Y	Y	N	Y	Y	7
Lau <i>et al.</i> [44]	2017	Y	N	Y	Y	Y	Y	Y	Y	8
Yilmaz <i>et al.</i> [31]	2018	Y	Y	Y	N	Y	Y	Y	Y	8
Banerjee <i>et al.</i> [33]	2019	Y	Y	Y	Y	N	Y	Y	Y	7
Zhang <i>et al.</i> [45]	2020	Y	N	Y	Y	Y	Y	Y	Y	8
Heiland <i>et al.</i> [9]	2021	Y	Y	Y	N	Y	N	Y	Y	7
Paradise <i>et al.</i> [34]	2021	Y	Y	Y	N	Y	Y	Y	Y	8
Retrospective or cross-sectional										
Charidimou <i>et al.</i> [13]	2013	Y	Y	Y	Y	N	Y	Y	Y	7
Burnett <i>et al.</i> [12]	2014	Y	Y	Y	Y	N	Y	Y	Y	7
Arba <i>et al.</i> [28]	2016	Y	Y	Y	Y	Y	N	Y	Y	8
Arba <i>et al.</i> [21]	2016	Y	N	Y	Y	Y	N	Y	Y	7
Song <i>et al.</i> [38]	2016	Y	Y	Y	Y	Y	N	Y	Y	8
Zhang <i>et al.</i> [19]	2016	Y	Y	Y	Y	N	Y	Y	Y	7
Shams <i>et al.</i> [30]	2017	Y	Y	Y	Y	N	Y	Y	Y	7
Xiong <i>et al.</i> [32]	2018	Y	Y	Y	Y	N	Y	Y	Y	7
Wan <i>et al.</i> [36]	2018	Y	Y	Y	Y	Y	N	Y	Y	8
Lioutas <i>et al.</i> [35]	2018	Y	Y	Y	Y	Y	N	Y	Y	8
Liang <i>et al.</i> [10]	2018	Y	Y	Y	Y	N	Y	Y	Y	7
Del Brutto <i>et al.</i> [37]	2019	Y	Y	Y	Y	N	Y	Y	Y	7
Del Brutto <i>et al.</i> [39]	2019	Y	Y	Y	Y	N	Y	Y	Y	7
Del Brutto <i>et al.</i> [40]	2019	Y	N	Y	Y	Y	Y	Y	Y	8
Aribisala <i>et al.</i> [41]	2019	Y	Y	Y	Y	Y	N	Y	Y	8
Sim <i>et al.</i> [22]	2020	Y	Y	Y	Y	Y	N	Y	Y	8
Wang <i>et al.</i> [42]	2020	Y	N	Y	Y	Y	N	Y	Y	7
Ramirez <i>et al.</i> [11]	2021	Y	Y	Y	Y	Y	N	Y	Y	8
Xu <i>et al.</i> [46]	2021	Y	N	Y	Y	Y	Y	Y	Y	8
Song <i>et al.</i> [47]	2021	Y	Y	Y	Y	N	Y	Y	Y	7
Yang <i>et al.</i> [20]	2022	Y	Y	Y	Y	Y	N	Y	Y	8

Y – yes, N – no.

ing to depressive symptoms [57, 58]. A cross-sectional study by Patankar *et al.* [56] also showed that EPVS were associated with an increased risk of depression and a poorer response to antidepressants, which was consistent with our overall findings. However, Zhang *et al.* [19] did not find a clear association between EPVS and poststroke depression (PSD). These differences may be related to differences in study populations and designs, particularly in the assessment of PSD and EPVS. Future research should address these issues.

At present, the evidence regarding the association between EPVS and stroke is inconsistent,

and our results show that there was no statistically significant association between EPVS and stroke. The study of Francis *et al.* also found no significant association between the two [17]. However, some studies have shown that CS EPVS are associated with lobar intracerebral hemorrhage ($p = 0.041$), and BG EPVS are associated with non-CAA-induced intracerebral hemorrhage (OR = 3.58, 95% CI: 1.70–7.54) [13]. Since few studies have examined the association between EPVS and stroke, we did not perform separate analyses of ischemic and hemorrhagic stroke. Given the different pathophysiological mechanisms and clinical manage-




Figure 2. Forest plot of associations between enlarged perivascular spaces and cognitive impairment



ment of these conditions, the associations of EPVS with ischemic and hemorrhagic stroke should be evaluated separately in future studies.

Our results have important implications for understanding the relationship between EPVS and clinical symptoms, but several limitations remain. The sources of heterogeneity may include the following: (1) differences in study populations; (2) differences in study designs; (3) differences in sample sizes; (4) differences in EPVS detection and evaluation methods. Future studies should adopt more consistent, objective, and quicker methods to quantify EPVS. The potential of automated methods to assess EPVS burden has recently been recognized. Boespflug *et al.* [59] developed a method for fully automatic identification and segmentation of EPVS based on multimodal MRI images. However, this technique requires multiple MRI sequences, which may increase scanning time. Dubost *et al.* [6] developed a method for automated identification and quantitative assessment of EPVS using only T2-weighted MRI.

Second, while most studies used ORs, a few used HRs [9, 32, 43–45]. In meta-analyses, pooling HRs with ORs, although numerically similar to



each other, may not be methodologically appropriate and may affect the validity of the pooled estimates. Although the sensitivity analysis indicated that our results were robust, the inclusion of different effect measures remains a methodological limitation. In addition, due to the limited number of studies, we could not explore the relationship between EPVS in different regions and movement disorder and depressive symptoms, and high-quality cohort studies require longer follow-up. Although our results did not show statistically significant evidence of publication bias, our findings require further validation in future large prospective studies and meta-analyses using standardized EPVS classification criteria and statistical methods.

In conclusion, our results provide evidence for an association between EPVS and clinical symptoms, indicating that EPVS are associated with an increased risk of cognitive impairment, motor impairment, sleep disturbances, and depressive symptoms, but not with a significantly increased risk of stroke. In subgroup analyses, we found that BG EPVS were more strongly associated with cognitive impairment and sleep disturbance, and

A. Forest plot of associations of Enlarged Perivascular Spaces and Motor Disorder**B.** Forest plot of associations of Enlarged Perivascular Spaces and Sleep Disorder**Figure 3.** Forest plot of associations between enlarged perivascular spaces and motor impairment and sleep disturbance**Table V.** Begg's test

Begg's test	Value
Cognitive impairment	Pr > z = 0.426
Motor impairment	Pr > z = 1.000
Sleep disturbance	Pr > z = 0.061
Depressive symptoms	Pr > z = 0.327
Stroke	Pr > z = 0.079

CS EPVS were more strongly associated with depressive symptoms. Therefore, the presence of EPVS may warrant attention to associated clinical symptoms and risk factors, and further research is needed to determine whether EPVS can be used to identify individuals at increased risk of these outcomes and to investigate potential preventive and therapeutic strategies. Furthermore, future research should continue to optimize automated

A. Forest plot of associations of Enlarged Perivascular Spaces and Depressive Disorder**B.** Forest plot of associations of Enlarged Perivascular Spaces and Stroke**Figure 4.** Forest plot of associations of Enlarged Perivascular Spaces and Depressive Disorder and Stroke

EPVS quantification methods, including improvements in algorithms, MRI acquisition sequences, and post-processing techniques.

Ethical approval

Not applicable.

Funding

Hebei Provincial Government-funded clinical Talents Training Project (201906).

Conflict of interest

The authors declare no conflict of interest.

References

1. Brown R, Benveniste H, Black SE, et al. Understanding the role of the perivascular space in cerebral small vessel disease. *Cardiovasc Res* 2018; 114: 1462-73.
2. Wang X, Chappell FM, Valdes Hernandez M, et al. Endothelial function, inflammation, thrombosis, and basal ganglia perivascular spaces in patients with stroke. *J Stroke Cerebrovasc Dis* 2016; 25: 2925-931.
3. Debette S, Schilling S, Duperron MG, et al. Clinical significance of magnetic resonance imaging markers of vascular brain injury: a systematic review and meta-analysis. *JAMA Neurol* 2019; 76: 81-94.
4. Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. *Lancet Neurol* 2013; 12: 822-38.
5. Rudie JD, Rauschecker AM, Nabavizadeh SA, et al. Neuroimaging of dilated perivascular spaces: from benign and pathologic causes to mimics. *J Neuroimaging* 2018; 28: 139-49.
6. Dubost F, Yilmaz P, Adams H, et al. Enlarged perivascular spaces in brain MRI: automated quantification in four regions. *Neuroimage* 2019; 185: 534-44.
7. Potter GM, Chappell FM, Morris Z, et al. Cerebral perivascular spaces visible on magnetic resonance imaging: development of a qualitative rating scale and its observer reliability. *Cerebrovasc Dis* 2015; 39: 224-31.
8. Jie W, Lin G, Liu Z, et al. The relationship between enlarged perivascular spaces and cognitive function: a meta-analysis of observational studies. *Front Pharmacol* 2020, 11: 715.
9. Heiland EG, Welmer AK, Kalpouzos G, et al. Cerebral small vessel disease, cardiovascular risk factors, and future walking speed in old age: a population-based cohort study. *BMC Neurol* 2021; 21: 496.
10. Liang Y, Chan YL, Deng M, et al. Enlarged perivascular spaces in the centrum semiovale are associated with poststroke depression: a 3-month prospective study. *J Affect Disord* 2018; 228: 166-72.
11. Ramirez J, Holmes MF, Berezuk C, et al. MRI-visible perivascular space volumes, sleep duration and daytime dysfunction in adults with cerebrovascular disease. *Sleep Med* 2021; 83: 83-8.
12. Burnett MS, Witte RJ, Ahlskog JE. Swiss cheese striatum: clinical implications. *JAMA Neurol* 2014; 71: 735-41.
13. Charidimou A, Meegahage R, Fox Z, et al. Enlarged perivascular spaces as a marker of underlying arteriopathy in intracerebral haemorrhage: a multicentre MRI cohort study. *J Neurol Neurosurg Psychiatry* 2013; 84: 624-9.
14. Iadecola C. The pathobiology of vascular dementia. *Neuron* 2013; 80: 844-66.
15. Postrzech-Adamczyk K, Nahorecki A, Jacków-Nowicka J, et al. Magnetic resonance white matter changes in patients with obstructive sleep apnoea. The subset of the PURE-MIND (Prospective Urban and Rural Epidemiological) cohort study. *Arch Med Sci* 2021; 22: 169-74.
16. Wardlaw JM, Benveniste H, Nedergaard M, et al. Perivascular spaces in the brain: anatomy, physiology and pathology. *Nat Rev Neurol* 2020; 16: 137-53.
17. Francis F, Ballerini L, Wardlaw JM. Perivascular spaces and their associations with risk factors, clinical disorders and neuroimaging features: a systematic review and meta-analysis. *Int J Stroke* 2019; 14: 359-71.
18. Van Sloten TT, Sigurdsson S, Van Buchem MA, et al. Cerebral small vessel disease and association with higher incidence of depressive symptoms in a general elderly population: the AGES-Reykjavik Study. *Am J Psychiatry* 2015; 172: 570-8.
19. Zhang X, Tang Y, Xie Y, et al. Total magnetic resonance imaging burden of cerebral small-vessel disease is associated with post-stroke depression in patients with acute lacunar stroke. *Eur J Neurol* 2017; 24: 374-80.
20. Yang S, Yin J, Qin W, et al. Poor sleep quality associated with enlarged perivascular spaces in patients with lacunar stroke. *Front Neurol* 2021; 12: 809217.
21. Arba F, Quinn TJ, Hankey GJ, et al. Enlarged perivascular spaces and cognitive impairment after stroke and transient ischemic attack. *Int J Stroke* 2018; 13: 47-56.
22. Sim JE, Park MS, Shin HY, et al. Correlation between hippocampal enlarged perivascular spaces and cognition in non-demented elderly population. *Front Neurol* 2020; 11: 542511.
23. Bakker EN, Bacskaï BJ, Arbel-Ornath M, et al. Lymphatic clearance of the brain: perivascular, paravascular and significance for neurodegenerative diseases. *Cell Mol Neurobiol* 2016; 36: 181-94.
24. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol* 2010; 25: 603-5.
25. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002; 21: 1539-58.
26. Zhu YC, Dufouil C, Soumare A, et al. High degree of dilated Virchow-Robin spaces on MRI is associated with increased risk of dementia. *J Alzheimers Dis* 2010; 22: 663-72.
27. Yao M, Zhu YC, Soumare A, et al. Hippocampal perivascular spaces are related to aging and blood pressure but not to cognition. *Neurobiol Aging* 2014; 35: 2118-25.
28. Arba F, Quinn T, Hankey GJ, et al. Cerebral small vessel disease, medial temporal lobe atrophy and cognitive status in patients with ischaemic stroke and transient ischaemic attack. *Eur J Neurol* 2017; 24: 276-82.
29. Riba-Llena I, Nafria C, Mundet X, et al. Assessment of enlarged perivascular spaces and their relation to target organ damage and mild cognitive impairment in patients with hypertension. *Eur J Neurol* 2016; 23: 1044-50.
30. Shams S, Martola J, Charidimou A, et al. Topography and determinants of magnetic resonance imaging (MRI)-visible perivascular spaces in a large memory clinic cohort. *J Am Heart Assoc* 2017; 6: e006279.
31. Yilmaz P, Ikram MK, Niessen WJ, et al. Practical small vessel disease score relates to stroke, dementia, and death. *Stroke* 2018; 49: 2857-65.
32. Xiong L, Boulouis G, Charidimou A, et al. Dementia incidence and predictors in cerebral amyloid angiopathy patients without intracerebral hemorrhage. *J Cereb Blood Flow Metab* 2018; 38: 241-9.
33. Banerjee G, Chan E, Ambler G, et al. Effect of small-vessel disease on cognitive trajectory after atrial fibrillation-related ischaemic stroke or TIA. *J Neurol* 2019; 266: 1250-9.
34. Paradise M, Crawford JD, Lam BC, et al. Association of dilated perivascular spaces with cognitive decline and incident dementia. *Neurology* 2021; 96: e1501-11.
35. Lioutas VA, Wu B, Norton C, et al. Cerebral small vessel disease burden and functional and radiographic outcomes in intracerebral hemorrhage. *J Neurol* 2018; 265: 2803-14.
36. Wan Y, Hu W, Gan J, et al. Exploring the association between cerebral small-vessel diseases and motor symptoms in Parkinson's disease. *Brain Behav* 2019; 9: e01219.
37. Del Brutto OH, Peinado CD, Mera RM, et al. Neuroimaging signatures of cerebral small vessel disease and risk

- of falls in stroke-free older adults living in rural Ecuador. The Atahualpa Project. *J Neurol Sci* 2019; 402: 133-5.
38. Song TJ, Park JH, Choi KH, et al. Moderate-to-severe obstructive sleep apnea is associated with cerebral small vessel disease. *Sleep Med* 2017; 30: 36-42.
 39. Del Brutto OH, Mera RM, Del Brutto VJ, et al. Enlarged basal ganglia perivascular spaces and sleep parameters. A population-based study. *Clin Neurol Neurosurg* 2019; 182: 53-7.
 40. Del Brutto OH, Mera RM, Del Brutto VJ, et al. Lack of association between periodic limb movements during sleep and neuroimaging signatures of cerebral small vessel disease in stroke-free community-dwelling older adults. The Atahualpa Project. *J Stroke Cerebrovasc Dis* 2020; 29: 104497.
 41. Aribisala B S, Riha R L, Valdes Hernandez M, et al. Sleep and brain morphological changes in the eighth decade of life. *Sleep Med* 2020; 65: 152-8.
 42. Wang J, Chen X, Liao J, et al. Non breathing-related sleep fragmentation and imaging markers in patients with atherosclerotic cerebral small vessel disease (CSVD): a cross-sectional case-control study. *BMC Neurol* 2020; 20: 98.
 43. Gutierrez J, Elkind MSV, Dong C, et al. Brain perivascular spaces as biomarkers of vascular risk: results from the Northern Manhattan Study. *AJNR Am J Neuroradiol* 2017; 38: 862-7.
 44. Lau KK, Li L, Lovelock CE, et al. Clinical correlates, ethnic differences, and prognostic implications of perivascular spaces in transient ischemic attack and ischemic stroke. *Stroke* 2017; 48: 1470-7.
 45. Zhang J, Han F, Liang X, et al. Lacune and large perivascular space: two kinds of cavities are of different risk factors and stroke risk. *Cerebrovasc Dis* 2020; 49: 522-30.
 46. Xu M, Cheng Y, Zhang S, et al. Higher cerebral small vessel disease burden is associated with smaller hematoma volume in mixed-location intracerebral hemorrhage. *Microcirculation* 2021; 28: e12705.
 47. Song Q, Cheng Y, Wang Y, et al. Enlarged perivascular spaces and hemorrhagic transformation after acute ischemic stroke. *Ann Transl Med* 2021; 9: 1126.
 48. Lim J S, Kim N, Jang M U, et al. Cortical hubs and subcortical cholinergic pathways as neural substrates of post-stroke dementia. *Stroke* 2014; 45: 1069-76.
 49. Rasmussen MK, Mestre H, Nedergaard M. The glymphatic pathway in neurological disorders. *Lancet Neurol* 2018; 17: 1016-24.
 50. Xie L, Kang H, Xu Q, et al. Sleep drives metabolite clearance from the adult brain. *Science* 2013; 342: 373-7.
 51. Kang MK, Koo DL, Shin JH, et al. Association between periodic limb movements during sleep and cerebral small vessel disease. *Sleep Med* 2018; 51: 47-52.
 52. Bereczuk C, Ramirez J, Gao F, et al. Virchow-Robin spaces: correlations with polysomnography-derived sleep parameters. *Sleep* 2015; 38: 853-8.
 53. Iliff JJ, Lee H, Yu M, et al. Brain-wide pathway for waste clearance captured by contrast-enhanced MRI. *J Clin Invest* 2013; 123: 1299-309.
 54. Iliff JJ, Wang M, Liao Y, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β . *Sci Transl Med* 2012; 4: 147ra111.
 55. Pinter D, Ritchie S J, Doubal F, et al. Impact of small vessel disease in the brain on gait and balance. *Sci Rep* 2017; 7: 41637.
 56. Patankar T F, Baldwin R, Mitra D, et al. Virchow-Robin space dilatation may predict resistance to antidepressant monotherapy in elderly patients with depression. *J Affect Disord* 2007; 97: 265-70.
 57. Shi Y, Xiang Y, Yang Y, et al. Depression after minor stroke: prevalence and predictors. *J Psychosom Res* 2015; 79: 143-7.
 58. Zhang Y, Wang C, Sun C, et al. Neural complexity in patients with poststroke depression: a resting EEG study. *J Affect Disord* 2015; 188: 310-8.
 59. Boespflug EL, Schwartz DL, Lahna D, et al. MR Imaging-based multimodal autoidentification of perivascular spaces (mMAPS): automated morphologic segmentation of enlarged perivascular spaces at clinical field strength. *Radiology* 2018; 286: 632-42.